search
Back to results

The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients

Primary Purpose

Type 2 Diabetes

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
SP2086
Sponsored by
Jiangsu HengRui Medicine Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patient has a definitive diagnosis of Type 2 Diabetes.
  • BMI(a measure of a person's weight in relation to height)is between 19 and 30 kg/m2,and the weight is equal or greater than 50kg.
  • Never use the antidiabetic or only use one type oral antidiabetic(except the insulin secretagogues agent).
  • The patient never use insulin in 3 months of screening.
  • Be willing to accept physical contraception.
  • Sign the informed consents voluntarily and ensure to completed the study.

Exclusion Criteria:

  • The value of fasting blood-glucose(FBG)>13.9mmol/L,or HbA1c>10.0%;
  • Known allergy to SP2086 or any of the excipients of the formulation of SP2086;
  • Type 1 diabetes,or Gestational diabetes,or other type diabetes;
  • ever occured acute complications of diabetes such as diabetic ketoacidosis,high permeability syndrome or lactic acidosis.
  • ever occured the severe hypoglycemia.
  • History of chronic complication of diabetes(kidney disease,or retinopathy,neuropathy,or lower limb vascular lesion).
  • The value of serum creatinine over the upper limit of normal range.
  • ever occured myocardial infarction,acute coronary syndrome, transient ischemic attack.
  • QTc interval>450ms(male) or >470ms(female) or have the history of cardiac insufficiency which the NYHA(New York Heart Association) class over I degree.
  • have the history of hypertension,and not well control:SBP(Systolic Blood Pressure)>140 mmHg or DBP(Diastolic Blood Pressure)>90 mmHg.
  • have the history of cancer.
  • the value of ALT and/or AST was greater two times of upper limit of normal range,or the STB over the 1.5 times of upper limit of normal range.
  • the B hepatitis surface antigen or hepatitis C antibody or syphilis antibody or HIV antibody was positive.
  • had participated three or more clinical trial in one year or had participated one time clinical medicine in one month of screening.
  • have the history of blood donation in 3 months of screening or received the blood transfusion in 1 months of screening.
  • have the history of tobacco,alcohol or drug abuse.
  • History of or current clinically significant medical illness as determined by the Investigator.

Sites / Locations

  • the First Hosital of Jilin UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

SP2086 50mg

SP2086 100mg

SP2086 200mg

Arm Description

there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.

there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.

there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.

Outcomes

Primary Outcome Measures

The maximum plasma concentration (Cmax) of SP2086
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
The steady-state plasma concentration (Css) of SP2086
Css (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086
The maximum plasma concentration (Cmax) of SP2086 acid
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
The steady-state plasma concentration (Css) of SP2086 acid
Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086
The maximum urine concentration (Cmax) of SP2086
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
The steady-state urine concentration (Css) of SP2086
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
The maximum urine concentration (Cmax) of SP2086 acid
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
The steady-state urine concentration (Css) of SP2086 acid
Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086

Secondary Outcome Measures

The number of volunteers with adverse events as a measure of safety and tolerability

Full Information

First Posted
June 30, 2016
Last Updated
June 30, 2016
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02822534
Brief Title
The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients
Official Title
the Pharmacokinetics,Pharmacodynamics,Safety and Tolerability Study Following Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Unknown status
Study Start Date
April 2016 (undefined)
Primary Completion Date
July 2016 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and PK/PD profiles of SP2086 in Type 2 Diabetes Patients .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SP2086 50mg
Arm Type
Experimental
Arm Description
there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
Arm Title
SP2086 100mg
Arm Type
Experimental
Arm Description
there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
Arm Title
SP2086 200mg
Arm Type
Experimental
Arm Description
there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
Intervention Type
Drug
Intervention Name(s)
SP2086
Intervention Description
the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
Primary Outcome Measure Information:
Title
The maximum plasma concentration (Cmax) of SP2086
Description
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
Time Frame
up to Day 13
Title
The steady-state plasma concentration (Css) of SP2086
Description
Css (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086
Time Frame
up to Day 13
Title
The maximum plasma concentration (Cmax) of SP2086 acid
Description
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
Time Frame
up to Day 13
Title
The steady-state plasma concentration (Css) of SP2086 acid
Description
Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086
Time Frame
up to Day 13
Title
The maximum urine concentration (Cmax) of SP2086
Description
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
Time Frame
up to Day 13
Title
The steady-state urine concentration (Css) of SP2086
Description
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
Time Frame
up to Day 13
Title
The maximum urine concentration (Cmax) of SP2086 acid
Description
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
Time Frame
up to Day 13
Title
The steady-state urine concentration (Css) of SP2086 acid
Description
Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086
Time Frame
up to Day 13
Secondary Outcome Measure Information:
Title
The number of volunteers with adverse events as a measure of safety and tolerability
Time Frame
up to Day 13

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient has a definitive diagnosis of Type 2 Diabetes. BMI(a measure of a person's weight in relation to height)is between 19 and 30 kg/m2,and the weight is equal or greater than 50kg. Never use the antidiabetic or only use one type oral antidiabetic(except the insulin secretagogues agent). The patient never use insulin in 3 months of screening. Be willing to accept physical contraception. Sign the informed consents voluntarily and ensure to completed the study. Exclusion Criteria: The value of fasting blood-glucose(FBG)>13.9mmol/L,or HbA1c>10.0%; Known allergy to SP2086 or any of the excipients of the formulation of SP2086; Type 1 diabetes,or Gestational diabetes,or other type diabetes; ever occured acute complications of diabetes such as diabetic ketoacidosis,high permeability syndrome or lactic acidosis. ever occured the severe hypoglycemia. History of chronic complication of diabetes(kidney disease,or retinopathy,neuropathy,or lower limb vascular lesion). The value of serum creatinine over the upper limit of normal range. ever occured myocardial infarction,acute coronary syndrome, transient ischemic attack. QTc interval>450ms(male) or >470ms(female) or have the history of cardiac insufficiency which the NYHA(New York Heart Association) class over I degree. have the history of hypertension,and not well control:SBP(Systolic Blood Pressure)>140 mmHg or DBP(Diastolic Blood Pressure)>90 mmHg. have the history of cancer. the value of ALT and/or AST was greater two times of upper limit of normal range,or the STB over the 1.5 times of upper limit of normal range. the B hepatitis surface antigen or hepatitis C antibody or syphilis antibody or HIV antibody was positive. had participated three or more clinical trial in one year or had participated one time clinical medicine in one month of screening. have the history of blood donation in 3 months of screening or received the blood transfusion in 1 months of screening. have the history of tobacco,alcohol or drug abuse. History of or current clinically significant medical illness as determined by the Investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yanhua Ding, docter
Phone
0431-88782168
Email
dingyanhua2003@126.com
Facility Information:
Facility Name
the First Hosital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanhua Ding, docter
Phone
0431-88782168
Email
dingyanhua2003@126.com

12. IPD Sharing Statement

Learn more about this trial

The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients

We'll reach out to this number within 24 hrs